Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.27 -3.4%	$2.09	$1.05 ▼ $4.13	$355.06M	1.96	616,360 shs	675,982 shs
AQST Aquestive Therapeutics	$3.35 -5.4%	$2.80	$2.12 ▼ $5.80	$339.70M	1.94	1.54 million shs	1.67 million shs
BYSI BeyondSpring	$3.40 +13.3%	$1.76	$0.98 ▼ $3.44	$112.48M	0.07	28,694 shs	138,282 shs
CMPX Compass Therapeutics	$2.19 -7.6%	$2.02	$0.77 ▼ $4.08	$333.26M	1.41	948,832 shs	797,072 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-3.23%	-10.91%	+74.13%	+78.90%	+15.99%
AQST Aquestive Therapeutics	-5.37%	-6.42%	+40.76%	+12.42%	+22.71%
BYSI BeyondSpring	+13.33%	+35.46%	+104.82%	+109.88%	+21.43%
CMPX Compass Therapeutics	-7.59%	-12.75%	+4.29%	-3.10%	+87.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	2.6058 of 5 stars	3.5	3.0	0.0	0.0	3.0	0.8	0.6
AQST Aquestive Therapeutics	1.5232 of 5 stars	3.5	1.0	0.0	0.0	3.3	0.0	0.0
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	3.7343 of 5 stars	4.6	1.0	0.0	0.0	3.4	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$8.50	160.34% Upside
AQST Aquestive Therapeutics	3.00	Buy	$10.14	202.77% Upside
BYSI BeyondSpring	0.00	N/A	N/A	N/A
CMPX Compass Therapeutics	3.11	Buy	$13.13	499.32% Upside

Current Analyst Ratings Breakdown

Latest BYSI, CMPX, ADCT, and AQST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/4/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $24.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.57	N/A	N/A	($2.10) per share	-1.55
AQST Aquestive Therapeutics	$57.56M	5.78	N/A	N/A	($0.66) per share	-5.08
BYSI BeyondSpring	$1.75M	78.34	N/A	N/A	($0.37) per share	-9.19
CMPX Compass Therapeutics	$850K	356.27	N/A	N/A	$0.91 per share	2.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
AQST Aquestive Therapeutics	-$44.14M	-$0.59	N/A	N/A	N/A	-100.02%	N/A	-50.31%	8/5/2025 (Estimated)
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)

Latest BYSI, CMPX, ADCT, and AQST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/12/2025	Q1 2025	BYSI BeyondSpring	N/A	-$0.06	N/A	$0.11	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
3/27/2025	Q4 2024	ADCT ADC Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$19.01 million	$19.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
AQST Aquestive Therapeutics	N/A	4.87	4.48
BYSI BeyondSpring	N/A	2.49	2.49
CMPX Compass Therapeutics	N/A	8.33	8.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
AQST Aquestive Therapeutics	32.45%
BYSI BeyondSpring	40.29%
CMPX Compass Therapeutics	68.43%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
AQST Aquestive Therapeutics	7.85%
BYSI BeyondSpring	29.31%
CMPX Compass Therapeutics	29.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.53 million	Optionable
BYSI BeyondSpring	80	40.32 million	28.50 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable

BYSI, CMPX, ADCT, and AQST Headlines

Recent News About These Companies

SG Americas Securities LLC Buys 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

June 16 at 3:48 AM | marketbeat.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of "Buy" by Analysts

June 16 at 1:20 AM | marketbeat.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC

June 15 at 3:19 AM | marketbeat.com

Head-To-Head Survey: Scilex (NASDAQ:SCLX) & Compass Therapeutics (NASDAQ:CMPX)

June 13, 2025 | americanbankingnews.com

Insider Buying: Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Buys 10,000 Shares of Stock

May 29, 2025 | marketbeat.com

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Thomas J. Schuetz Purchases 10,000 Shares

May 28, 2025 | insidertrades.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Buy" from Brokerages

May 24, 2025 | marketbeat.com

Tang Capital Management LLC Has $8.56 Million Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

May 20, 2025 | marketbeat.com

Stifel Nicolaus Sticks to Its Buy Rating for Compass Therapeutics (CMPX)

May 11, 2025 | theglobeandmail.com

Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Down 5.62%

May 10, 2025 | aaii.com

Compass Therapeutics price target lowered to $10 from $12 at Guggenheim

May 9, 2025 | msn.com

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

May 8, 2025 | globenewswire.com

Compass Therapeutics to Participate in Upcoming May Investor Events

May 6, 2025 | globenewswire.com

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

April 28, 2025 | globenewswire.com

2 Penny stocks to buy in May 2025

April 27, 2025 | finbold.com

Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Down 6.65%

April 26, 2025 | aaii.com

Compass Therapeutics Doses First Patient in Investigator Sponsored Trial of Tovecimig for Biliary Tract Cancer

April 23, 2025 | nasdaq.com

Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX) and UnitedHealth (UNH)

April 23, 2025 | markets.businessinsider.com

Compass Therapeutics announces first patient dosed in IST evaluating tovecimig

April 22, 2025 | markets.businessinsider.com

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

April 21, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, CMPX, ADCT, and AQST Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.26 -0.12 (-3.40%)

Closing price 06/17/2025 03:59 PM Eastern

Extended Trading

$3.32 +0.06 (+1.84%)

As of 04:14 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Aquestive Therapeutics NASDAQ:AQST

$3.35 -0.19 (-5.37%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$3.55 +0.20 (+5.94%)

As of 04:05 AM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

BeyondSpring NASDAQ:BYSI

$3.40 +0.40 (+13.33%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$3.30 -0.11 (-3.09%)

As of 06/17/2025 07:59 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Compass Therapeutics NASDAQ:CMPX

$2.19 -0.18 (-7.59%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$2.24 +0.05 (+2.47%)

As of 04:27 AM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time